A new kidney cancer drug is turning heads. Updated data from the ARC-20 trial show that casdatifan — an oral HIF-2α inhibitor — delivered strong response rates and survival outcomes in patients with advanced clear cell renal cell carcinoma (ccRCC), whether used alone or in combination, across first-, second-, and later-line settings. A phase 3 trial is already underway.
A new kidney cancer drug is turning heads. Updated data from the ARC-20 trial reveal that casdatifan, an investigational oral HIF-2α inhibitor developed by Arcus Biosciences, showed meaningful antitumor activity in advanced clear cell renal cell carcinoma (ccRCC) across multiple treatment lines — both as a standalone therapy and in combination with other agents.
The drug works by blocking HIF-2α, a protein that drives tumor growth in ccRCC when the von Hippel-Lindau tumor-suppressor gene is lost. Notably, no unexpected safety signals emerged across any of the cohorts, and the company is on track to launch a first-line registrational trial (PEAK-20) by year's end.
By the Numbers:
Why it matters: These results suggest casdatifan could become a foundational treatment across all lines of ccRCC therapy — a significant development for a cancer with limited options after progression on standard treatments. The ongoing phase 3 PEAK-1 trial will provide the randomized data needed to confirm its benefit.
